# Registry Study of Revcovi Treatment in Patients With ADA-SCID

> **NCT03878069** · — · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 32 (actual)

## Conditions studied

- Adenosine Deaminase Severe Combined Immunodeficiency

## Interventions

- **BIOLOGICAL:** elapegademase-lvlr

## Key facts

- **NCT ID:** NCT03878069
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-30
- **Primary completion:** 2023-01-18
- **Final completion:** 2023-01-18
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878069, "Registry Study of Revcovi Treatment in Patients With ADA-SCID". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03878069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*